Pubblicazioni

Autori:

Vicenzi, Edoardo Bruno; Cesaro, Simone

Titolo:

Posaconazole in immunocompromised pediatric patients

Anno:

2018

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY

ISSN Rivista:

1478-7210

N° Volume:

16

Numero o Fascicolo:

7

Intervallo pagine:

543-553

Parole chiave:

Invasive fungal infections; pediatric malignancy; posaconazole; prophylaxis; treatment; Age Factors; Antifungal Agents; Child; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Immunocompromised Host; Invasive Fungal Infections; Off-Label Use; Triazoles

Breve descrizione dei contenuti:

Posaconazole is a broad-spectrum triazole widely used to prevent and treat invasive mycoses in adults. Since it received marketing authorization more than a decade ago, many authors have reported on its off-label use in pediatric patients, despite the fact that the pharmacokinetics, safety, and efficacy in children have not been extensively investigated. Areas covered: We reviewed pediatric studies published between 2010 and 2017 describing the prophylactic and therapeutic use of posaconazole, with special attention to the correlation between oral dose, plasma levels, safety, and effectiveness. We found that posaconazole is well tolerated in children with a low incidence of adverse effects. As in adults, posaconazole absorption is hampered by factors such as high gastric pH, mucositis, and concomitant medications, whereas there is no direct correlation between the daily dose and the trough plasma concentration due to saturable absorption. Expert Commentary: Posaconazole has proved safe and effective in preventing and treating fungal infections in immunocompromised children. A body-weight-based dosing regimen and therapeutic drug monitoring are recommended to optimize posaconazole plasma concentration. Absorption can be improved by high-fat foods or avoiding the use of proton-pump inhibitors. Further pediatric studies are needed especially for the new formulations of posaconazole (vials and tablets).

Id prodotto:

106302

Handle IRIS:

11562/990437

ultima modifica:

2 dicembre 2022

Citazione bibliografica:

Vicenzi, Edoardo Bruno; Cesaro, Simone, Posaconazole in immunocompromised pediatric patients «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY» , vol. 16 , n. 7 , 2018 , pp. 543-553

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo